Kathleen M. Mahoney, MD, PhD | Authors

SPECIALTY HOSPITAL ALBUQUERQUE

235 ELM ST NE

Articles

Prognostic and Predictive Markers for the New Immunotherapies

November 10, 2014

Characterizing tumors by PD-L1 expression, immune infiltration, chemokine signature, and tumor mutational frequency may be a means of creating an integrated model for determining which patients may benefit from which immune-checkpoint inhibitors, either alone or in combination.